OTHER Research papers

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832.
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network

IBD-EII platform to help share evidence-based data regarding IBD in a summarized way.

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Journal of Crohn's and Colitis, 27 January 2023, jjad015
Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study

The Lancet Gastroenterology and Hepatology, February 01, 2023
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA)

Nat Rev Gastroenterol Hepatol . OCTOBER 2022
Dietary management of adults with IBD - the emerging role of dietary therapy

Lancet Gastroenterol Hepatol . 2022 OCTOBER 2022
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

Research papers

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

IBD-EII platform to help share evidence-based data regarding IBD in a summarized way.

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031 Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023 Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Journal of Crohn's and Colitis, 27 January 2023, jjad015 Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study

The Lancet Gastroenterology and Hepatology, February 01, 2023 Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA)

Nat Rev Gastroenterol Hepatol . OCTOBER 2022 Dietary management of adults with IBD - the emerging role of dietary therapy

Lancet Gastroenterol Hepatol . 2022 OCTOBER 2022 Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832.
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Journal of Crohn's and Colitis, 27 January 2023, jjad015
Patient reported outcomes and disability are associated with histological disease activity in patients with ulcerative colitis: results from the APOLLO study

The Lancet Gastroenterology and Hepatology, February 01, 2023
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA)

Nat Rev Gastroenterol Hepatol . OCTOBER 2022
Dietary management of adults with IBD - the emerging role of dietary therapy

Lancet Gastroenterol Hepatol . 2022 OCTOBER 2022
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial